CAVATAK is a proprietary formulation of the common cold Coxsackievirus
Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types.
One group of researchers showed that a normally benign strain of coxsackievirus
becomes virulent and damages the heart when administered to selenium-deficient mice.
Drug profiles discussed in this report are CEL-1000, Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation, Cell Therapy to Target Flt3L for Autoimmune Myocarditis, chagas disease vaccine, Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders, OBR-5340 and Small Molecule to Inhibit Coxsackievirus
B3 3C Protease for Myocarditis.
Bioaron C[R] inhibited the replication of human rhinovirus and coxsackievirus
, both viruses belonging to the family of picornaviridae and both representing non-enveloped RNA viruses.
A16 encephalitis during obinutuzumab therapy, Belgium, 2013.
The incriminated infectious agents reported to date are rubella, Echovirus 7, mumps, cytomegalovirus, parainfluenza, coxsackievirus
, adenovirus, influenza A, human herpes virus 6, hepatitis B, parvovirus B19, Epstein-Barr virus, Yersinia enterocolitica, Chlamydophila pneumoniae, Mycoplasma pneumoniae, Brucella abortus, and Borrelia burgdorferi.
Viralytics' lead investigational product, CAVATAK, is a proprietary formulation of the common cold Coxsackievirus
Type A21 (CVA21).
When mice were fed a selenium-deficient diet and then inoculated with a nonvirulent strain of Coxsackievirus
B3, the virus mutated to become a virulent strain.
Apoptosis in coxsackievirus
B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva.
Enterovirusler picornavirus ailesinden olup; Coxsackievirus
A ve B, Echovirus ve daha yeni numaralandirilmis enterovirus 68-71 ve poliovirusleri icerir.
Serum microRNA expression profile distinguishes enterovirus 71 and coxsackievirus
16 infections in patients with hand-foot-and-mouth disease.
But they cautioned that there was no evidence the vaccine would cross-protect against another virus called coxsackievirus
A 16, which is often found circulating with EV71 and also causes hand foot and mouth disease.